Upgrade to SI Premium - Free Trial

Altimmune (ALT)

2.96 +0.19 (6.86%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Leerink Starts Altimmune (ALT) at Outperform June 22, 2026 6:31 AM - StreetInsider Form 8-K Altimmune, Inc. For: Jun 16 June 16, 2026 4:07 PM - SEC Filing Altimmune (ALT) Reiterated at Market Outperform By Citizens After EASL Presentation June 2, 2026 4:28 AM - StreetInsider Altimmune reports metabolic improvements for MASH drug pemvidutide May 28, 2026 11:00 AM - StreetInsider Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 May 28, 2026 11:00 AM - Globe NewsWire Altimmune to Participate in Upcoming Investor Conferences May 27, 2026 8:30 AM - Globe NewsWire Altimmune presents phase 2b trial data showing pemvidutide liver benefits May 27, 2026 8:01 AM - StreetInsider New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 May 27, 2026 8:00 AM - Globe NewsWire Altimmune (ALT) PT Lowered to $20 at H.C. Wainwright May 19, 2026 6:46 AM - StreetInsider Form SCHEDULE 13G/A Altimmune, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC May 15, 2026 4:22 PM - SEC Filing Altimmune (ALT) PT Lowered to $11 at Citizens on Increased Dilutive Shares in 10-Q Filing May 14, 2026 4:45 AM - StreetInsider Form S-8 Altimmune, Inc. May 13, 2026 4:18 PM - SEC Filing Form 10-Q Altimmune, Inc. For: Mar 31 May 13, 2026 4:14 PM - SEC Filing Altimmune (ALT) PT Lowered to $18 at Evercore ISI May 13, 2026 4:05 PM - StreetInsider Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities May 13, 2026 8:33 AM - StreetInsider Altimmune, Inc. (ALT) Tops Q1 EPS by 6c May 13, 2026 7:44 AM - StreetInsider Form 8-K Altimmune, Inc. For: May 13 May 13, 2026 7:34 AM - SEC Filing Altimmune Announces First Quarter 2026 Financial Results and Business Update May 13, 2026 7:30 AM - Globe NewsWire Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026 May 13, 2026 7:15 AM - Globe NewsWire Form SCHEDULE 13G Altimmune, Inc. Filed by: STATE STREET CORP May 12, 2026 9:46 AM - SEC Filing Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 May 6, 2026 7:30 AM - Globe NewsWire Form SCHEDULE 13G Altimmune, Inc. Filed by: VIKING GLOBAL INVESTORS LP May 1, 2026 5:39 PM - SEC Filing Form SCHEDULE 13G Altimmune, Inc. Filed by: TCG Crossover GP II, LLC May 1, 2026 4:37 PM - SEC Filing Form 4 Altimmune, Inc. For: May 01 Filed by: Lawver Teri L May 1, 2026 4:23 PM - SEC Filing Form 4 Altimmune, Inc. For: May 01 Filed by: Sohn Catherine A. May 1, 2026 4:21 PM - SEC Filing Form 4 Altimmune, Inc. For: May 01 Filed by: Jorkasky Diane May 1, 2026 4:19 PM - SEC Filing Form 4 Altimmune, Inc. For: May 01 Filed by: Schafer Klaus May 1, 2026 4:16 PM - SEC Filing Form 4 Altimmune, Inc. For: May 01 Filed by: Pisano Wayne May 1, 2026 4:14 PM - SEC Filing Form 4 Altimmune, Inc. For: May 01 Filed by: Hodges Philip May 1, 2026 4:11 PM - SEC Filing Form SCHEDULE 13G Altimmune, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P. May 1, 2026 4:11 PM - SEC Filing Form 4 Altimmune, Inc. For: May 01 Filed by: GILL JOHN May 1, 2026 4:09 PM - SEC Filing Form 4 Altimmune, Inc. For: May 01 Filed by: SAYARE MITCHEL May 1, 2026 4:06 PM - SEC Filing Form SCHEDULE 13G Altimmune, Inc. Filed by: Deep Track Capital, LP April 30, 2026 4:00 PM - SEC Filing Full Article List